Knockdown of the long noncoding RNA VSIG2-1:1 promotes the angiogenic ability of human pulmonary microvascular endothelial cells by activating the VEGF/PI3K/AKT pathway Authors: Xiaoya Hu, Yihui Zheng, Mingchu Fang, Zhongjie Liang, Chao Wen, Jing Lin, Zhenlang Lin, Shangqin Chen Published: 2024 ABSTRACT BackgroundAbnormal pulmonary vascular development poses significant clinical challenges for infants with bronchopulmonary dysplasia (BPD). Although numerous factors have been suggested to control the development of pulmonary blood vessels, the mechanisms underlying the role of long noncoding RNAs (lncRNAs) in this process remain unclear.MethodsA lncRNA array was used to measure the differential expression of lncRNAs in premature infants with and without BPD. The expression of lncRNA-VSIG2-1:1 in patients with BPD and hyperoxia-induced human pulmonary microvascular endothelial cells (HPMECs) was assessed using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Fluorescence in situ hybridization (FISH) assay was performed to detect the subcellular localization of lncRNA-VSIG2-1:1. Pulmonary microvascular endothelial cells were stably transfected with adenoviral vectors to silence or overexpress lncRNA-VSIG2-1:1. The effects of lncRNA-VSIG2-1:1 on the proliferation, migration, and tube formation abilities of HPMECs subjected to hyperoxia were examined by performing Cell Counting Kit‐8 (CCK-8), cell migration, and tubule formation assays. RNA sequencing (RNA-seq) was performed to determine the correlation between lncRNA-VSIG2-1:1 and phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT). The protein levels of vascular endothelial growth factor (VEGF), p-PI3K, PI3K, p-AKT, and AKT were determined using western blotting.ResultsThe expression of lncRNA-VSIG2-1:1 was upregulated in patients with BPD and hyperoxia-treated HPMECs. Inhibiting lncRNA-VSIG2-1:1 expression promoted the proliferation, migration, and tube-formation abilities of HPMECs, while significantly increasing VEGF, p-PI3K, and p-AKT levels.ConclusionOur findings reveal that the suppression of lncRNA-VSIG2-1:1 expression stimulates angiogenesis in vitro by inducing the initiation of the VEGF/PI3K/AKT signaling pathway. This observation may aid the development of novel therapeutic targets for treating BPD.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12931-024-03039-y. Background Bronchopulmonary dysplasia (BPD) or chronic lung disease markedly affects the quality of life of surviving premature infants, especially those with an extremely low birth weight (ELBW) of < 1000 g. With the increased survival of ELBW infants owing to modern medicine, the incidence of BPD has also increased [1–3]. The causes of BPD are multifactorial and complex, and genetic susceptibility and differences in individual genetic regulation have attracted significant attention [4–6]. Pathophysiological changes in patients with BPD predominantly include simplified alveoli and dysmorphic vasculature [7–10]. In addition, normal alveolarization during lung development requires microvascular angiogenesis [11, 12]. Currently, the mechanisms underlying pulmonary vascular development in BPD are not fully understood and proper strategies for BPD treatment are lacking. Long noncoding RNAs (lncRNAs) are molecules that contain at least 200 nucleotides and do not encode proteins. Emerging evidence supports the significant involvement of lncRNAs in various cellular processes. Recent studies have shown the marked roles that lncRNAs play in angiogenesis and vascular disorders [13–15], thereby highlighting their potential as crucial biomarkers and therapeutic targets for various diseases. Although vascular endothelial cells are important for both vascular repair and angiogenesis [16–18], their role in the regulation and expression of lncRNAs in angiogenesis remains poorly understood. Vascular endothelial growth factor (VEGF) activity considerably affects angiogenesis and the development of vascular systems [19–21]. During angiogenesis, VEGF facilitates the growth and movement of cells in the endothelium and the formation of vascular tubules. Its role in lung development is crucial, and changes in its expression are associated with the occurrence of BPD and chronic lung disease [22, 23]. A previous study has established that VEGF can control the in vivo expression of immune genes at the local level, suggesting its potential application in exogenous therapy for various lung diseases [24, 25]. Moreover, several studies have presented evidence of the essential functions of phosphoinositide-3-kinase (PI3K) and protein kinase B (Akt) in promoting the survival of endothelial cells and facilitating angiogenesis. These mechanisms are induced by VEGF activation [26–29]. In the present study, we aimed to investigate the involvement of lncRNA-VSIG2-1:1 in the development and pathogenesis of BPD through the VEGF/PI3K/AKT signaling pathway to identify a novel therapeutic target for treating infants afflicted by BPD. For the sake of simplicity, the lncRNA-VSIG2-1:1is referred to as VSIG2 moving forward. We first evaluated VSIG2 expression in premature infants with BPD and compared the results with VSIG2 expression in matched controls. Next, we investigated the functional and potential molecular mechanisms of action of VSIG2 in vitro. The examination of RNA sequencing (RNA-seq) data revealed a marked increase in the expression of PI3K/AKT pathway-associated genes, of which the expression levels were regulated by VSIG2. Methods Collection of blood samples Between January and December 2021, the Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University enrolled six preterm neonates diagnosed with BPD and six preterm neonates without BPD of the same age. BPD was diagnosed based on the diagnostic criteria set by the Children’s Health and Human Development guidelines [30]. Venous blood collection tubes containing ethylenediaminetetraacetic acid were used to collect whole-blood samples, followed by centrifugation (2000 rpm, 20 min) for plasma separation. The expression profile of lncRNA was analyzed using Agilent-085202 LC Human ceRNAarray (lncRNA version) provided by LC Biotechnology (Hangzhou, China) Co., Ltd. This study was approved by the Clinical Ethics Committee of the Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University (Approval No.: LS 2021-K-311-03), and written informed consent was obtained from the guardians of the newborns. Cell culture Human pulmonary microvascular endothelial cells (HPMECs) used in this study were purchased from iCell Bioscience Inc. (Shanghai, China) and cultured in a specialized extracellular matrix medium. This medium contained 10% heat-inactivated fetal bovine serum (FBS) and an endothelial cell growth supplement. The cells were maintained at a CO2 concentration of 5% and temperature of 37 °C. Hyperoxia exposure Hyperoxia tests were conducted inside a tightly sealed plexiglass enclosure, wherein a gas blend consisting of 95% O2 and 5% CO2 was circulated. This water-jacketed insulation protected the chamber, which was maintained at 37 °C in a Forma Scientific™ incubator. After the O2 level in the chamber reached 95%, the cells were promptly introduced into the chamber and incubated for 48 h [31]. Cell transfection and treatment Adenoviral vectors were used to knock down or overexpress VSIG2, whereas lentiviral vectors were constructed to knock down VEGF. All vectors were acquired from Sangon Biotech Co., Ltd (Shanghai, China). The plasmid sequences (5′ → 3′) were as follows: sh-VSIG2-1:1-1: GGTGATAGCTACCACTTAATTCAAGAGATTAAGTGGTAGCTATCACCTTTTTT; sh-VSIG2-1:1–2: GAGGGAGAAACAGGATGAATTCAAGAGATTCATCCTGTTTCTCCCTCTTTTTT; sh-VSIG2-1:1–3: CCGTGTTCATTACCTTTGATTCAAGAGATCAAAGGTAATGAACACGGTTTTTT sh-VEGF-1: CGAGGCAGCTTGAGTTAAATTCAAGAGATTTAACTCAAGCTGCCTCGTTTTTT sh-VEGF-2: GATCCGCAGACGTGTAAATTTCAAGAGAATTTACACGTCTGCGGATCTTTTTT sh-VEGF-3: GAGCGGAGAAAGCATTTGTTTCAAGAGAACAAATGCTTTCTCCGCTCTTTTTT The transfected cells were exposed to an oxygenated cell culture system for 48 h preceding further experiments. Subsequently, these carriers were transfected into the cells. Transfection was performed using Lipofectamine 3000 (Thermo Fisher Scientific) according to the manufacturer’s instructions and under suitable cellular conditions. Real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) Total RNA was extracted from the cultured cells and blood samples using the TRIzol reagent (Beyotime, Shanghai, China). A Nanodrop 2000 Spectrophotometer (Thermo Fisher Scientific) was used to quantify the samples. ReverTra Ace qPCR Master Mix (TOYOBO, Japan) was used to prepare the complementary DNA. PCR-based real-time quantitative analysis was performed using an Applied Biosystems 7900HT Fast Real-Time PCR System with SYBR Green Real-Time PCR Master Mix (TOYOBO, Japan). The following primer sequences (5′ → 3′) were used: Lnc-VSIG2-1:1-F: CAGGATTCTTTGGGCGGT; Lnc-VSIG2-1:1-R: GACCGAAGAAGAACTGAGCATT; VEGF-F: TCAGCGCAGCTACTGCCATC VEGF-R: GTGCTGGCCTTGGTGAGGTT GAPDH-F: TGGGTGTGAACCATGAGAAGT; GAPDH-R: TGAGTCCTTCCACGATACCAA Cell counting kit-8 (CCK-8) assay The CCK-8 (Beyotime, Shanghai, China) was used to assess cell proliferation. A total of 3000 cells were seeded in each well of 96-well plates and incubated for 12, 24, 48, and 72 h. Subsequently, 10 µL of the CCK-8 reagent was added to each well, and the plates were subjected to incubation at 37 °C for 1 h. To determine cell viability, absorbance (optical density [OD]) was measured at 450 nm using a microplate reader (Bio-Tek Instruments, Inc. United States). Cell migration assay The migratory ability of the cells was evaluated by performing a scratch assay. In six-well plates, 2 × 105 cells were seeded and incubated for 24 h. After a 4-h period of serum deprivation, we created a linear scratch on the surface of the cell monolayer using a 10 µL pipette tip. Subsequently, a phosphate-buffered saline (PBS) solution was applied thrice to the cells. The cells were cultured for an additional 24 h in serum-free medium at 37 °C in the presence of 5% CO2. The migration distance results were analyzed using ImageJ software. Tube formation assay A Matrigel tubule formation assay was performed to assess the angiogenic effect of HPMECs in vitro [32, 33]. HPMECs were transfected with either the control or sh-VSIG2/OE-VSIG2 constructs and subjected to normoxia or hyperoxia for 48 h. A total of 4 × 105 cells were suspended in growth factor reduced Matrigel solution (50 µL) and seeded into wells coated with Matrigel. After incubation for 24 h, tubule formation was analyzed using ImageJ software. Western blotting Total protein was extracted using radioimmunoprecipitation assay (RIPA) buffer, and the Beyotime Bicinchoninic Acid (BCA) Protein Assay Kit (China) was used for protein quantification. The proteins were separated using sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) with a concentration range of 8–12%, followed by transfer onto polyvinylidene fluoride (PVDF) membranes provided by Millipore (USA). Following a 2-h blockage of the membranes using 5% nonfat milk, we incubated the membranes overnight with primary antibodies at 4 °C. The following five antibodies were used: anti-VEGF (#65373, 1:1000, CST), anti-t-PI3K (ab40776, 1:1000, Abcam), anti-p-PI3K (#4228, 1:1000, CST), anti-t-AKT (#9272,1:1000, CST), and anti-p-AKT antibodies (#9275, 1:1000, CST). Next, secondary antibodies conjugated with horseradish peroxidase (HRP; AS003,1:5000, Abclonal) were used and incubated at room temperature for 2 h. Signals were detected using the Super Enhanced Chemiluminescence (ECL) Plus Kit (Sangon, C520001). The data were analyzed using Gel Pro Analyzer. RNA-seq analysis We transfected HPMECs with the lentivirus sh-VSIG2 or sh-control. Total RNA was extracted from each group using the TRIzol reagent and sequenced at Sangon Biotech Co., Ltd (Shanghai, China) using the Illumina HiSeq PE150 platform. The RNA-seq data were processed in the FASTA format after FASTP data quality evaluation and filtering. The following criteria were used to identify differentially expressed genes (DEGs): transcripts per million (TPM) of ≥ 5 in at least one sample, absolute log2fold_change value of > 1, and q-value of < 0.05. The obtained DEGs were analyzed by performing the Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway enrichment analysis, with the significance level set at p < 0.05. Fluorescence in situ hybridization (FISH) FISH was performed following the established protocols. The probe sequence for VSIG2_(AGCTATCACCATAATTCCCTTCTTCCTCATAAGCACACCC)_was designed accordingly. The cells were cultured in an atmosphere containing 95% O2 and 5% CO2 and fixed for 20 min in 4% paraformaldehyde (PFA). Following a single PBS wash, the cells were exposed in a dropwise manner to a pre-hybridization solution, followed by incubation for 1 h at 37 °C. Following the removal of the pre-hybridization solution, the cells were incubated at 37 °C overnight with RNA probes in hybridization buffer. The cells were washed in with saline sodium citrate (SSC) buffer for 10 min at 37 °C after the hybridization, followed by washing twice in 1 × SSC at the same temperature for 5 min each time and finally in 0.5 × SSC at room temperature for 10 min. Next, 4′,6-diamidino-2-phenylindole (DAPI) solution was added to the samples, followed by incubation under light protection for 8 min before sealing the slices with an anti-fluorescence quenching agent. The Zeiss laser confocal microscope (Nikon) was used for imaging. Statistical data analysis Data were analyzed statistically using GraphPad Prism 8 software, with the data presented as mean ± standard deviation (SD). Student’s t-tests were used for group comparisons, whereas one-or two-way analysis of variance (ANOVA) with Bonferroni's test was used to compare multiple groups. All experiments were repeated in triplicate to ensure validity and reproducibility. Statistical significance was set at p < 0.05. Results lncRNA-VSIG2-1:1 expression was upregulated in patients with BPD and hyperoxia-induced HPMECs We identified differentially expressed lncRNAs in patients with BPD compared with those in gestational age-matched controls using a lncRNA expression microarray. Among the differentially expressed lncRNAs, 635 were upregulated and 572 were downregulated (Fig. 1a). The top 50 significant DEGs were defined based on p < 0.05 (Fig. 1b). VSIG2 was upregulated in the patients when compared with its expression in the controls. We established an in vitro model using HPMECs. qRT-PCR verified that VSIG2 was overexpressed in the BPD group (n = 6) and hyperoxia-induced HPMECs, whereas its expression in the control group (n = 4) and normoxia-induced cells was low (Fig. 1c, d). In HPMECs, the expression of VSIG2 was the highest with 95% O2 exposure at 48 and 72 h (Fig. 1e). The presence of VSIG2 in the nucleus was confirmed using RNA FISH (Fig. 1f). The predominant nuclear localization of VSIG2 in HPMECs suggests its potential involvement in regulating gene expression within the nuclear milieu.Fig. 1VSIG2 expression in patients with BPD and hyperoxia-exposed HPMECs. a Volcano plot showing the differential expression of lncRNAs in patients with BPD compared with that in the controls. b Heat map displaying the top 50 significant DEGs in the lncRNA microarray assay. c VSIG2 expression in the plasma of patients with BPD (n = 6) and controls (n = 4) was determined using qRT-PCR, with GAPDH serving as a reference gene. d VSIG2 expression was relatively low under normoxic conditions (21%) compared with that under hyperoxic conditions (95%) for 48 h, as determined using qRT-PCR, with GAPDH serving as the reference gene. e VSIG2 expression levels were measured at different time-points (24, 48, and 72 h). f VSIG2 localization in HPMECs was determined using FISH. Values are presented as mean ± SD. *p < 0.05, **p < 0.01, ****p < 0.0001 VSIG2 expression in patients with BPD and hyperoxia-exposed HPMECs. a Volcano plot showing the differential expression of lncRNAs in patients with BPD compared with that in the controls. b Heat map displaying the top 50 significant DEGs in the lncRNA microarray assay. c VSIG2 expression in the plasma of patients with BPD (n = 6) and controls (n = 4) was determined using qRT-PCR, with GAPDH serving as a reference gene. d VSIG2 expression was relatively low under normoxic conditions (21%) compared with that under hyperoxic conditions (95%) for 48 h, as determined using qRT-PCR, with GAPDH serving as the reference gene. e VSIG2 expression levels were measured at different time-points (24, 48, and 72 h). f VSIG2 localization in HPMECs was determined using FISH. Values are presented as mean ± SD. *p < 0.05, **p < 0.01, ****p < 0.0001 The effect of lncRNA-VSIG2-1:1 on the angiogenesis of HPMECs in vitro The effect of modulating the expression of VSIG2 on HPMECs was investigated in vitro. VSIG2 was successfully upregulated in HPMECs through an adenoviral vector. The viability of the cells was evaluated by performing the CKK-8 assay, which indicated that the overexpression of VSIG2 resulted in a reduction in cell growth (Fig. 2a). The scratch test results showed that the migration abilities of HPMECs overexpressing VSIG2 were significantly impaired compared with those of the control HPMECs (Fig. 2b). Moreover, the results of the tube formation assay demonstrated that HPMECs transfected with a VSIG2 overexpression vector, exhibited a diminished ability to form tubes compared with that of the cells transfected with the control vector (Fig. 2c). These findings suggest that VSIG2 inhibits angiogenesis in HPMECs in vitro.Fig. 2Effect of VSIG2 overexpression on HPMEC function. a Cell viability of the HPMECs was assessed using the CCK-8 assay. b Migration ability of the HPMECs was examined using a scratch assay. Migration distances were quantified and the percentage of migrated cells were calculated. c Experimental detection of the tube formation ability of HPMECs based on the number and length of tubes formed. Values are presented as mean ± SD. *p < 0.05 Effect of VSIG2 overexpression on HPMEC function. a Cell viability of the HPMECs was assessed using the CCK-8 assay. b Migration ability of the HPMECs was examined using a scratch assay. Migration distances were quantified and the percentage of migrated cells were calculated. c Experimental detection of the tube formation ability of HPMECs based on the number and length of tubes formed. Values are presented as mean ± SD. *p < 0.05 Knockdown of lncRNA-VSIG2-1:1 promoted angiogenesis of HPMECs in vitro To evaluate the effect of lncRNA-VSIG2-1:1 inhibition on HPMECs, we stably transfected the cells using an adenoviral vector targeting VSIG2 to suppress its expression in HPMECs. Among the three candidate shRNAs, sh-VSIG2-1:1-1 was most effective in VSIG2 knockdown (Fig. 3a). The CCK-8 cell proliferation assay revealed a notable enhancement in the proliferative potential of HPMECs following VSIG2 downregulation (Fig. 3b). Furthermore, the migratory ability of HPMECs significantly increased following the knockdown of VSIG2 compared with that of the control cohort (Fig. 3c). In addition, sh-VSIG2-transfected cells exhibited enhanced tube-formation ability compared with that of cells transfected with the control vector (Fig. 3d). Therefore, our in vitro findings suggest that VSIG2 silencing promotes angiogenesis in HPMECs.Fig. 3VSIG2 knockdown using shRNA may enhance angiogenesis in HPMECs. a qRT-PCR analysis for measuring VSIG2 expression in HPMECs treated with shRNAs. b Viability of the HPMECs was assessed using the CCK-8 assay. c Migration ability of the HPMECs was examined using a scratch assay. Migration distances were quantified and the percentage of migrated cells was calculated. d Experimental detection of the tube formation-ability of HPMECs based on the number and length of tubes formed. Values are presented as mean ± SD. *p < 0.05, **p < 0.01, and****p < 0.0001 VSIG2 knockdown using shRNA may enhance angiogenesis in HPMECs. a qRT-PCR analysis for measuring VSIG2 expression in HPMECs treated with shRNAs. b Viability of the HPMECs was assessed using the CCK-8 assay. c Migration ability of the HPMECs was examined using a scratch assay. Migration distances were quantified and the percentage of migrated cells was calculated. d Experimental detection of the tube formation-ability of HPMECs based on the number and length of tubes formed. Values are presented as mean ± SD. *p < 0.05, **p < 0.01, and****p < 0.0001 lncRNA-VSIG2-1:1 participates in angiogenesis through the VEGF/PI3K/AKT signaling pathway To understand the role of VSIG2 in HPMEC angiogenesis, RNA-seq was performed on HPMECs transfected with sh-VSIG2 or sh-control. A total of 3454 genes showing differential expression, which is, DEGs, were observed in the sh-VSIG2 and negative control groups (972 genes were downregulated and 2482 genes were upregulated; Fig. 4a). To gain a deeper understanding of biological functions, we performed a KEGG pathway enrichment analysis of these DEGs (Fig. 4b). The KEGG pathway analysis revealed a significant increase in the number of DEGs across multiple pathways, including the PI3K/AKT signaling pathway, interaction between cytokines and cytokine receptors, mitogen-activated protein kinase (MAPK) signaling pathway, interaction between neuroactive ligands and receptors, and axon guidance. The DEGs showed the strongest enrichment within the PI3K/AKT pathway.Fig. 4Transcriptional genes of VSIG2 in HPMECs. Relative protein expression in the different groups. a Scatterplot analysis was performed to examine differential gene expression in HPMECs transfected with sh-VSIG2 or sh-control. Red, blue, and gray represent the upregulated genes, downregulated genes, and genes with non-significant changes in expression, respectively. b KEGG enrichment analysis. The Scatter-plot shows the differential gene expression between the sh-VSIG2 and sh-control groups. c qRT-PCR analysis was performed to assess the mRNA expression of VEGF in OE-VSIG2 or sh-VSIG2 cells compared with that in the cells transfected with the vector or NC. d, e Western blot analysis was performed to detect VEGF, t-PI3K, t-AKT, p-PI3K, and p-AKT levels in OE-VSIG2 or sh-VSIG2 cells compared with those in the cells transfected with the vector or NC. GAPDH served as the loading control. The western blotting images used for quantification are presented in Supplementary Fig. S1. Values are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 Transcriptional genes of VSIG2 in HPMECs. Relative protein expression in the different groups. a Scatterplot analysis was performed to examine differential gene expression in HPMECs transfected with sh-VSIG2 or sh-control. Red, blue, and gray represent the upregulated genes, downregulated genes, and genes with non-significant changes in expression, respectively. b KEGG enrichment analysis. The Scatter-plot shows the differential gene expression between the sh-VSIG2 and sh-control groups. c qRT-PCR analysis was performed to assess the mRNA expression of VEGF in OE-VSIG2 or sh-VSIG2 cells compared with that in the cells transfected with the vector or NC. d, e Western blot analysis was performed to detect VEGF, t-PI3K, t-AKT, p-PI3K, and p-AKT levels in OE-VSIG2 or sh-VSIG2 cells compared with those in the cells transfected with the vector or NC. GAPDH served as the loading control. The western blotting images used for quantification are presented in Supplementary Fig. S1. Values are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 The PI3K/AKT pathway contributes to various essential cellular functions, such as proliferation, attachment, movement, infiltration, metabolism, and angiogenesis [34–36]. This pathway involves multiple differential genes, with VEGF emerging as a key player. Considering their effect on HPMEC angiogenesis, we hypothesized that the regulation of HPMEC angiogenesis by VSIG2 involves the modulation of the VEGF and PI3K/AKT pathways. Therefore, we investigated the effect of VSIG2 knockdown on VEGF expression. VEGF expression was significantly upregulated after VSIG2 knockdown (Fig. 4c). To determine PI3K and AKT protein levels and the levels of their phosphorylated forms in HPMECs, western blot analysis was performed after depleting VSIG2 expression using shRNA. Furthermore, VSIG2 knockdown activated PI3K/AKT signaling, whereas VSIG2 upregulation suppressed it (Fig. 4d, e). We co-transfected sh-VEGF (Fig. 5a) and sh-VSIG2 into HPMECs and performed assays to examine the proliferation (Fig. 5b), migration (Fig. 5d–f), and tube-formation abilities of the cells (Fig. 5h, i, k, and l). The results revealed that sh-VEGF effectively counteracted the VSIG2 knockdown-induced enhancement of angiogenesis. Next, we treated VSIG2-knockdown HPMECs with a PI3K/AKT inhibitor (HY-144806) and evaluated the effect on the proliferation (Fig. 5c), migration (Fig. 5d, e, and g), and tubule-generation abilities of the cells (Fig. 5h, j, k, and l). The results showed that PI3K/AKT-IN-1 attenuated the VSIG2 knockdown-induced enhancement of these processes.Fig. 5Knockdown of VSIG2 activates the PI3K/AKT pathway by regulating VEGF, thus facilitating HPMEC angiogenesis. a qRT-PCR analysis was performed to assess the VEGF expression in HPMECs treated with shRNAs. b HPMECs were co-transfected with sh-VSIG2 and sh-VEGF or transfected with the corresponding controls. Cell viability was examined using the CCK-8 assay. c HPMECs with VSIG2 knockdown were treated with the PI3K/AKT inhibitor HY-144806; their viability was examined using CCK-8 assays. d-g Cell migration and h–l tube formation abilities of the HPMECs were assessed using scratch and tube-formation assays, respectively. m–n The phosphorylation levels of PI3K and AKT in HPEMCs were determined using western blotting. GAPDH served as the loading control. The western blotting images used for quantification are presented in Supplementary Fig. S2. Values are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 Knockdown of VSIG2 activates the PI3K/AKT pathway by regulating VEGF, thus facilitating HPMEC angiogenesis. a qRT-PCR analysis was performed to assess the VEGF expression in HPMECs treated with shRNAs. b HPMECs were co-transfected with sh-VSIG2 and sh-VEGF or transfected with the corresponding controls. Cell viability was examined using the CCK-8 assay. c HPMECs with VSIG2 knockdown were treated with the PI3K/AKT inhibitor HY-144806; their viability was examined using CCK-8 assays. d-g Cell migration and h–l tube formation abilities of the HPMECs were assessed using scratch and tube-formation assays, respectively. m–n The phosphorylation levels of PI3K and AKT in HPEMCs were determined using western blotting. GAPDH served as the loading control. The western blotting images used for quantification are presented in Supplementary Fig. S2. Values are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 Next, we performed western blot analysis using HPMECs co-transfected with sh-VEGF and sh-VSIG2 to determine p-PI3K and p-AKT levels. The results demonstrated that sh-VEGF prevented the VSIG2 knockdown-induced increases in p-PI3K and p-AKT levels (Fig. 5m, n). In summary, our in vitro experiments indicate that the inhibition of VSIG2 expression affect hyperoxia-induced angiogenesis in HPMECs by stimulating the PI3K/AKT pathway through the regulation of VEGF expression. Discussion Hyperoxia is a significant contributor to lung vascular damage in preterm infants; however, the precise molecular mechanisms underlying this phenomenon remain unclear. lncRNAs are essential regulators of transcriptional networks in angiogenesis and vascular diseases [13]. In the present study, we performed a LncRNA array analysis to study the differential expression of lncRNAs in the peripheral blood of infants with and without BPD. The expression of 638 lncRNAs, including lnc-VSIG2-1:1, was significantly higher in patients with BPD than in those without BPD. These results suggest that the lncRNA profiles are markedly altered in BPD-associated pathological processes. Alveolar capillary barrier formation relies significantly on HPMECs [37],which are also the primary target cells for hyperoxia-induced damage [38].The dysfunction of the barrier between air and blood contributes to an imbalance in the alveolar ventilation-to-blood flow ratio, leading to hypoxemia and hypercapnia in patients with BPD [39, 40]. In this study, the observed histopathological alterations corresponded to the distinctive features associated with BPD. The clinical manifestations of BPD primarily stem from its dependence on O2, whereas microvascular endothelial cells exhibit a heightened sensitivity to excessive O2 levels. These factors may contribute to the accelerated progression of BPD. Furthermore, clinical observations have shown that premature infants with similar birth conditions (such as the same gestational age and birth weight) exhibited varying outcomes of BPD. Currently, few reports exist regarding the biological functions and roles of lncRNA-VSIG2-1:1 in BPD. Thus, we established hyperoxia conditions in a laboratory setting to stimulate HPMECs, with the goal of reproducing the pathological features of BPD in vitro. The RNA levels of VSIG2 were assessed under varying O2 concentrations. As the O2 concentration and exposure duration increased, the experimental groups showed a noticeable increase in VSIG2 expression compared with that seen in the control group. VSIG2 downregulation in HPMECs significantly increased the migration, proliferation, and tube-formation abilities of endothelial cells. Conversely, VSIG2 upregulation exerted an inhibitory effect. These findings suggest that the presence of VSIG2 impedes capillary development in HPMEC models exposed to hyperoxia, resulting in a decrease in capillary density and a subsequently decrease in the available alveolar–capillary surface area for efficient gas exchange. Hyperoxia-induced vascular disorders, such as BPD [25, 41, 42] and retinopathy of prematurity [43–45], are characterized by alterations in VEGF signaling. VEGF signaling between epithelial and endothelial cells has been reported to be essential for promoting normal lung development after birth [46]. Previous studies have shown that inhibiting VEGF signaling hinders both pulmonary blood vessel and alveolar development [47–50]. Cells of endothelial origin multiply, migrate, and differentiate in response to VEGF. In the present study, the VEGF mRNA and protein levels increased significantly after VSIG2 knockdown in HPMECs. In addition, the rescue experiment showed that sh-VEGF reversed the enhancement of angiogenesis caused by VSIG2 knockdown. Our data suggest that VSIG2 inhibits angiogenesis by downregulating VEGF expression in HPMECs. PI3K/Akt signaling is crucial for numerous cellular processes, including proliferation, migration, invasion, adhesion, metabolism, survival [51–53], and angiogenesis [34, 53]; the activation and phosphorylation of substrates downstream of PI3K/AKT affect various biological functions. Based on this information and findings of the present study, we hypothesize that VSIG2 regulated HPMEC angiogenesis via the PI3K/AKT pathway. The present findings demonstrated a strong correlation between VSIG2 expression and PI3K/AKT pathway activation, which involved the following two crucial molecules: p-PI3K and p-AKT. Furthermore, the VSIG2 knockdown-induced enhancement of angiogenesis was attenuated by a PI3K/AKT inhibitor. To verify whether PI3K/AKT signaling was activated by VSIG2 through the regulation of VEGF expression, we co-transfected HPMECs with sh-VEGF and sh-VSIG2.Subsequently, p-PI3K and p-AKT levels were measured by Western blotting. We determined that sh-VEGF prevented the VSIG2 depletion-induced increases in the p-PI3K and p-AKT, suggesting that VSIG2 depletion stimulated PI3K/AKT activation by upregulating VEGF expression. We demonstrated that lncRNA-VSIG2-1:1was correlated with the VEGF/PI3K/AKT pathway, providing a novel explanation for hyperoxia-induced vascular disruption. However, our study does have certain limitations. First, the restricted sample size may not entirely validate the precision of the findings. Second, how VSIG2 exerts its role in different stages of BPD remains unclear. Future studies should explore the direct cellular mechanism in future investigations. Conclusions In summary, our findings show that lncRNA-VSIG2-1:1 may contribute to abnormal pulmonary vascular development in BPD by affecting HPMEC angiogenesis through the regulation of VEGF/PI3K/AKT signaling. This can serve as a target for the development of novel interventions for the treatment and prevention of BPD. Supplementary Information Additional file 1 Additional file 1